Second chance: new stroke treatment could save more brain tissue
NCT ID NCT07550296
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests whether giving a second dose of the clot-busting drug prourokinase can help stroke patients who have a blocked medium or large artery and don't show improvement one hour after the first dose. About 122 adults will be enrolled within 4.5 hours of stroke onset. The goal is to see if the extra dose can reopen the blocked vessel and improve recovery at 90 days, without causing dangerous bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prourokinase
What this could lead to
If successful, this could offer a new treatment option for stroke patients who don't respond to the first clot-busting drug, potentially reducing disability.
What could go wrong
This is a small, early-phase trial (122 participants) and may not confirm benefit. There is a risk of bleeding in the brain, which could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hui-Sheng Chen
RECRUITINGShenyang, None Selected, 110016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••